Mylan Tries To Escape Pharmacy's EpiPen Antitrust Suit

By Meghan Kelly · December 15, 2020, 5:46 PM EST

Mylan Pharmaceuticals has urged a Kansas federal judge to drop it from a suit alleging it inflated the price for the emergency allergy medication EpiPen, arguing the retail and online pharmacy...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

2:17-md-02785

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Case Title

KPH Healthcare Services, Inc. v. Mylan N.V. et al

Case Number

2:20-cv-02065

Court

Kansas

Nature of Suit

Anti-Trust

Date Filed

February 14, 2020

Featured Stories

Judges Wade Into Abortion Pill Access And Rx Pricing Fights No Photo Available

Hannah Albarazi

In a flurry of recent legal activity, courts across the country have been drawn into the nation's most contentious healthcare debates ... (more story)

Defining The 'Superior' Bid In Pfizer-Novo Legal Battle No Photo Available

Yeji Jesse Lee

Pfizer and Novo Nordisk's bidding war and legal fight over obesity biotech company Metsera is raising questions around what legally co... (more story)

Meet The Attys Behind Drugmakers' Conn. Price Cap Suit No Photo Available

Gianna Ferrarin

Attorneys from Goodwin Procter LLP and Wiggin and Dana LLP are teaming up to represent the Association for Accessible Medicines in its... (more story)